Nephroscan Generic Name & Formulations
Technetium Tc 99m succimer 1mg; per vial; lyophilized pwd for IV inj after reconstitution. After radiolabeling (with sodium pertechnetate Tc 99m + dilution), contains up to 1480MBq (40mCi) of technetium Tc 99m succimer in approx. 5mL volume.
Radioactive diagnostic agent.
Kit—1 (5 single-dose vials)
As an aid in the scintigraphic evaluation of renal parenchymal disorders.
Nephroscan Dosage and Administration
See full labeling. Give by IV inj (bolus). Administer 74–222MBq (2–6mCi). Begin image acquisition 1–4hrs post-inj. Severely reduced eGFR: delay image acquisition up to 6–24hrs.
See full labeling. Give by IV inj (bolus). Base dose on body wt. Administer 1.85MBq/kg (0.05mCi/kg) with a range of 19–74MBq (0.5–2mCi). Begin image acquisition 1–4hrs post-inj. Severely reduced eGFR: delay image acquisition up to 6–24hrs.
Nephroscan Boxed Warnings
Risk of radiation exposure. Should only be used by trained and experienced physicians in the safe use and handling of radionuclides to minimize radiation exposure. Have resuscitation equipment/medications readily available. Ensure adequate hydration; encourage frequent voiding post-administration. Advanced renal failure: may have an effect on image interpretation. Elderly. Pregnancy. Nursing mothers: interrupt and pump/discard breastmilk for at least 24hrs after administration.
Nephroscan Adverse Reactions
Urticaria, rash, pruritus, erythema, syncope, fever, nausea; hypersensitivity reactions.
Nephroscan Clinical Trials
Nephroscan Patient Counseling